Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies

INTRODUCTION: Teneligliptin, an antihyperglycemic agent belonging to the dipeptidyl peptidase-4 inhibitor class, is usually prescribed at a dose of 20 mg/day. In Japan, the dose can be increased to 40 mg/day if needed. We examined the treatment response when the teneligliptin dose was increased from...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadowaki, Takashi, Sasaki, Kazuyo, Ishii, Manabu, Matsukawa, Miyuki, Ushirogawa, Yoshiteru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104275/
https://www.ncbi.nlm.nih.gov/pubmed/29435909
http://dx.doi.org/10.1007/s13300-018-0372-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104275/
https://www.ncbi.nlm.nih.gov/pubmed/29435909
http://dx.doi.org/10.1007/s13300-018-0372-x

Ejemplares similares